LLY

Eli Lilly and Company

78
Fundamentals85/ 100
Valuation62/ 100
Upside potential72/ 100
Risk potential15/ 100

LLY has the edge over TKNO overall, supported by lower modeled downside and stronger fundamentals.

TKNO

Alpha Teknova, Inc.

61
Fundamentals65/ 100
Valuation50/ 100
Upside potential66/ 100
Risk potential48/ 100

TKNO's outlook is improving, though it still trails on the overall score.

LLY Fundamentals

MetricStatus
Healthy
Strong
Strong
Healthy

LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.

TKNO Fundamentals

MetricStatus
Healthy
Under pressure
Under pressure
Strong

TKNO's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.

LLY PE Valuation

CHEAPFAIREXPENSIVE37x74x111x147x
CHEAPFAIREXPENSIVE37x74x111x147x
LevelPEPriceVs current
Cheap27x$845-41%
Forward30x$1,427—
Current46x$1,427—
Fair48x$1,466+2.7%
Expensive85x$2,612+83%

Historical ranges are pointers, not guarantees.

LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.

TKNO PE Valuation

TKNO has no meaningful PE right now: it lost money over the past year.

LLY Forward outlook

MetricOutlook
Strongly improving
Strong growth
Strong growth
Strongly improving
Limited
Moderate

Analysts expect strong earnings and revenue growth for LLY, with profitability improving.

TKNO Forward outlook

MetricOutlook
--
Losses shrinking
Strong growth
Strongly improving
Limited
High

Analysts expect TKNO's losses to shrink, with revenue growing.

LLY Risk to reward

ScenarioChangePrice
Upside+39%$1,988.49
Downside-15%$1,209.08

Calculated from the latest close: $1,427.28 on Nov 12.

LLY has a better modeled risk to reward balance than TKNO, with more potential upside relative to its potential downside.

TKNO Risk to reward

ScenarioChangePrice
Upside+92%$15.93
Downside-48%$4.35

Calculated from the latest close: $8.29 on Nov 12.

TKNO trails LLY on modeled risk to reward, with less potential upside relative to its potential downside.

LLY Earnings Per Share

Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
QuarterTTM EPSYoY
Forward$46.82+52%
Q3 2026$30.81+51%
Q2 2026$29.80+95%
Q1 2026$28.15+129%
Q4 2025$22.95+96%
Q3 2025$20.44+121%
Q2 2025$15.30+88%
Q1 2025$12.29+81%
Q4 2024$11.71+102%

LLY has the edge over TKNO on earnings quality, reporting a profit while its opponent remains loss making.

TKNO Earnings Per Share

Q4 2023: $-1.16Q1 2024: $-1.05Q2 2024: $-0.93Q3 2024: $-0.74Q4 2024: $-0.57Q1 2025: $-0.46Q2 2025: $-0.40Q3 2025: $-0.33Q4 2025: $-0.32Q1 2026: $-0.31Q2 2026: $-0.30Q3 2026: $-0.28
Q4 2023: $-1.16Q1 2024: $-1.05Q2 2024: $-0.93Q3 2024: $-0.74Q4 2024: $-0.57Q1 2025: $-0.46Q2 2025: $-0.40Q3 2025: $-0.33Q4 2025: $-0.32Q1 2026: $-0.31Q2 2026: $-0.30Q3 2026: $-0.28
QuarterTTM EPSYoY
Q3 2026-$0.28+$0.05
Q2 2026-$0.30+$0.10
Q1 2026-$0.31+$0.15
Q4 2025-$0.32+$0.25
Q3 2025-$0.33+$0.41
Q2 2025-$0.40+$0.53
Q1 2025-$0.46+$0.59
Q4 2024-$0.57+$0.59

TKNO is still losing money, but far less than before: $0.28 per share over the past year, against $1.83 at its worst in mid-2023.

LLY Quarterly Revenue

Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
QuarterRevenueYoY
Q3 2026$24.4B+39%
Q2 2026$23B+48%
Q1 2026$19.8B+56%
Q4 2025$19.3B+43%
Q3 2025$17.6B+54%
Q2 2025$15.6B+38%
Q1 2025$12.7B+45%
Q4 2024$13.5B+45%

LLY has the edge over TKNO on sales, with stronger typical year-over-year growth.

TKNO Quarterly Revenue

Q4 2023: $8MQ1 2024: $9MQ2 2024: $10MQ3 2024: $10MQ4 2024: $9MQ1 2025: $10MQ2 2025: $10MQ3 2025: $10MQ4 2025: $10MQ1 2026: $11MQ2 2026: $12MQ3 2026: $13M
Q4 2023: $8MQ1 2024: $9MQ2 2024: $10MQ3 2024: $10MQ4 2024: $9MQ1 2025: $10MQ2 2025: $10MQ3 2025: $10MQ4 2025: $10MQ1 2026: $11MQ2 2026: $12MQ3 2026: $13M
QuarterRevenueYoY
Q3 2026$12.7M+22%
Q2 2026$12.2M+18%
Q1 2026$11.1M+13%
Q4 2025$10M+7.8%
Q3 2025$10.5M+9.2%
Q2 2025$10.3M+7%
Q1 2025$9.8M+5.4%
Q4 2024$9.3M+18%

TKNO's revenue has grown year over year for nine quarters in a row: $13M last quarter, up 22% from the same quarter a year ago.

LLY Free Cash Flow

Q4 2023: −$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
Q4 2023: −$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
QuarterFree cash flowYoY
Q3 2026$8.2B+22%
Q2 2026$7.8B+458%
Q1 2026$3B+1826%
Q4 2025$677.9M-31%
Q3 2025$6.7B+186%
Q2 2025$1.4B+476%
Q1 2025$156.1M-13%
Q4 2024$977.8M+$2.4B

LLY has the edge over TKNO on cash generation, producing positive trailing cash flow while its opponent burns cash.

TKNO Free Cash Flow

Q4 2023: −$3MQ1 2024: −$7MQ2 2024: −$3MQ3 2024: −$2MQ4 2024: −$2MQ1 2025: −$4MQ2 2025: −$2MQ3 2025: −$2MQ4 2025: −$810,000Q1 2026: −$4MQ2 2026: −$596,000Q3 2026: −$1M
Q4 2023: −$3MQ1 2024: −$7MQ2 2024: −$3MQ3 2024: −$2MQ4 2024: −$2MQ1 2025: −$4MQ2 2025: −$2MQ3 2025: −$2MQ4 2025: −$810,000Q1 2026: −$4MQ2 2026: −$596,000Q3 2026: −$1M
QuarterFree cash flowYoY
Q3 2026-$1.4M+$969K
Q2 2026-$596K+$1.7M
Q1 2026-$3.6M+$729K
Q4 2025-$810K+$693K
Q3 2025-$2.4M+$23K
Q2 2025-$2.3M+$645K
Q1 2025-$4.3M+$2.4M
Q4 2024-$1.5M+$1.7M

TKNO has burned cash in almost every quarter: −$6M over the past year, against −$10M the year before.

LLY Total Shares

Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
PeriodChange %Net change
Quarterly0%-300K shares
1 year-0.6%-5.4M shares
3 years-0.7%-6.4M shares
5 years-1.9%-17.4M shares
Available history-4.5%-42.3M shares

LLY has the edge over TKNO on shareholder dilution, with a more favorable share count trend.

TKNO Total Shares

Q1 2024: 41MQ2 2024: 41MQ3 2024: 52MQ4 2024: 47MQ1 2025: 53MQ2 2025: 53MQ3 2025: 54MQ4 2025: 53MQ1 2026: 54MQ2 2026: 54MQ3 2026: 54M
Q1 2024: 41MQ2 2024: 41MQ3 2024: 52MQ4 2024: 47MQ1 2025: 53MQ2 2025: 53MQ3 2025: 54MQ4 2025: 53MQ1 2026: 54MQ2 2026: 54MQ3 2026: 54M
PeriodChange %Net change
Quarterly+0.1%+59.6K shares
1 year+0.3%+177K shares
3 years+90%+25.4M shares
5 years+106%+27.6M shares

TKNO has 54M diluted shares, about the same as a year ago.

LLY Net Leverage

Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
QuarterNet LeverageStatus
Q3 20261.2xHealthy
Q2 20261.3xHealthy
Q1 20261.2xHealthy
Q4 20251.3xHealthy
Q3 20251.3xHealthy
Q2 20252.0xHealthy
Q1 20252.3xModerate
Q4 20242.1xModerate

LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.

TKNO Net Leverage

QuarterNet LeverageStatus
Q2 2021-47.1xNet Cash
Q1 2021-0.5xNet Cash
Q4 2020-0.5xNet Cash

TKNO has more cash than debt.

LLY Weekly Momentum

MetricValueStatus
RSI68.3Neutral
Stochastic84.1Overbought

LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).

TKNO Weekly Momentum

MetricValueStatus
RSI61.0Neutral
Stochastic64.2Neutral

TKNO's weekly RSI is 61 (neutral) and its Stochastic is 64 (neutral).

LLY PE vs Healthcare Sector

MetricLLYSector medianRelative
PE46x26x79% above
PE %482919 pts above

LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.

TKNO PE vs Healthcare Sector

TKNO has no meaningful PE right now: it lost money over the past year.

LLY Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1,279.412% above
20 week MA$1,218.817% above
50 week MA$1,102.229% above
100 week MA$954.150% above
200 week MA$797.579% above

LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.

TKNO Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$8.023.4% above
20 week MA$7.0218% above
50 week MA$4.9468% above
100 week MA$5.4153% above
200 week MA$4.4387% above

TKNO is in an uptrend: it's above all five of its weekly moving averages, and 87% above its 200-week average.

LLY Yearly ROI

YearStart priceEnd priceROI
2020$131.5$166.7+27%
2021$166.7$273.1+64%
2022$273.1$367.9+35%
2023$367.9$582.9+58%
2024$582.9$783.2+34%
2025$783.2$1,077.8+38%
2026 YTD$1,077.8$1,427.3+32%

LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.

TKNO Yearly ROI

YearStart priceEnd priceROI
2021$25.0$20.4-19%
2022$20.4$5.14-75%
2023$5.14$3.73-27%
2024$3.73$8.73+134%
2025$8.73$4.04-54%
2026 YTD$4.04$8.29+105%

TKNO has the edge over LLY on returns for 2026, with the stronger performance.

Give your agent the market.

Get API key